Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to “Strong Sell” at Zacks Research

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Tuesday,Zacks.com reports.

A number of other brokerages have also commented on KNSA. TD Cowen started coverage on shares of Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They issued a “buy” rating and a $60.00 price target for the company. Citigroup raised their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research note on Thursday, September 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and an average price target of $52.33.

Kiniksa Pharmaceuticals International Stock Down 4.8%

Shares of Kiniksa Pharmaceuticals International stock traded down $1.90 during trading on Tuesday, hitting $37.67. 188,455 shares of the stock traded hands, compared to its average volume of 649,974. Kiniksa Pharmaceuticals International has a 52 week low of $18.12 and a 52 week high of $44.42. The firm’s fifty day moving average is $41.34 and its 200-day moving average is $36.60. The stock has a market cap of $2.85 billion, a price-to-earnings ratio of 83.65 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm had revenue of $180.86 million for the quarter, compared to the consensus estimate of $166.64 million. During the same period last year, the company posted ($0.18) earnings per share. The business’s revenue was up 61.2% on a year-over-year basis. On average, analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Activity

In other news, insider John F. Paolini sold 82,542 shares of the stock in a transaction dated Friday, October 31st. The shares were sold at an average price of $37.14, for a total transaction of $3,065,609.88. Following the sale, the insider directly owned 61,324 shares of the company’s stock, valued at $2,277,573.36. This represents a 57.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Sanj K. Patel sold 97,390 shares of the business’s stock in a transaction that occurred on Wednesday, October 22nd. The shares were sold at an average price of $38.83, for a total value of $3,781,653.70. Following the completion of the sale, the chief executive officer owned 111,794 shares of the company’s stock, valued at $4,340,961.02. This trade represents a 46.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 510,689 shares of company stock valued at $20,009,290 over the last 90 days. Company insiders own 53.48% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds have recently added to or reduced their stakes in KNSA. Amundi acquired a new stake in Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after purchasing an additional 1,002 shares in the last quarter. Millennium Management LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after purchasing an additional 67,452 shares in the last quarter. Strs Ohio acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter valued at $595,000. Finally, Rhumbline Advisers boosted its position in Kiniksa Pharmaceuticals International by 6.4% during the first quarter. Rhumbline Advisers now owns 62,700 shares of the company’s stock worth $1,393,000 after acquiring an additional 3,745 shares during the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.